Author Archives: Iqra Mumal, MSc

European Vasculitis Experts Vote on New EULAR Recommendations

Members of the U.K.-based European Vasculitis Society (EUVAS) have accepted recently published recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, EUVAS clinicians don’t necessarily agree with the recommendations’ suggestion to use Rituxan (rituximab) to treat patients who have eosinophilic granulomatosis with polyangiitis (EGPA). The study, “Validation…

Eye Disease Affects About a Fifth of ANCA-associated Vasculitis Patients, Study Finds

About a fifth of ANCA-associated vasculitis patients have an eye disorder known as inflammatory ocular disease, a Mayo Clinic study shows. The research, published in the journal Rheumatology, was titled “Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study.” ANCA-associated vasculitis, or AAV, affects…

Changes in Certain T-cell Proteins May Contribute to Autoimmunity

Low levels of adenosine-regulating cell surface proteins on T-cells of patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis may contribute to autoimmunity, a new study suggests. The study, “Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over,”…

Research Collaboration in Rare Diseases Is Key to Improving Lives of Patients, Analysis Finds

International collaboration on research into rare diseases like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is fundamental to improving the health and lives of patients, a new study suggests. The review, titled “The importance of international collaboration for rare diseases research: a European perspective,” was published in the journal…

Rituxan Maintenance Therapy Reduces Relapse Rates in EGPA Patients, Study Finds

Patients with eosinophilic granulomatosis with polyangiitis (EGPA, or Churg-Strauss syndrome) who receive scheduled Rituxan (rituximab) therapy have lower relapse rates than those who are given Rituxan only during a relapse, a new study shows. The study titled, “Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis,” was…